Emergent Biosolutions (NYSE:EBS) Issues Earnings Results, Beats Expectations By $0.03 EPS

Emergent Biosolutions (NYSE:EBS) released its earnings results on Monday. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03, FiscalAI reports. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. The firm had revenue of $110.00 million for the quarter, compared to analyst estimates of $123.22 million.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Full-year 2026 revenue guidance was reduced to $600 million–$645 million, reflecting lower expected MCM revenue as some U.S. government and international deliveries may shift into early 2027; commercial revenue is tracking toward the low end of the expected 20%–25% decline versus 2025.
• The company generated $122 million in year-to-date operating cash flow, ended the quarter with $226 million in liquidity, and reduced gross debt to $514 million after repurchasing $75 million of bond principal.
• Emergent expects restructuring actions to deliver approximately $40 million in annualized savings, with initial benefits beginning in the fourth quarter, and raised adjusted gross-margin guidance to 45%–47% due to operational improvements, product mix, and more stable NARCAN pricing.
• Third-quarter revenue fell to $110 million from $231 million a year earlier, while adjusted EBITDA was negative $5 million, pressured by MCM delivery timing, product mix, and competitive pricing and volume pressure in the naloxone market.
• Emergent said NARCAN remains the U.S. market leader despite new competitors, while international MCM activity reached 13 countries and contributed 22% of year-to-date MCM revenue; the company is also advancing pan-Ebola, pan-flu, AI-enabled development, and other growth programs.

Emergent Biosolutions Trading Down 5.7%

EBS stock traded down $0.39 during midday trading on Monday, hitting $6.42. 944,168 shares of the company’s stock were exchanged, compared to its average volume of 970,465. The stock’s fifty day moving average price is $6.47 and its 200-day moving average price is $8.05. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. The company has a market cap of $329.36 million, a PE ratio of -1.81 and a beta of 2.37. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06.

Analyst Ratings Changes

A number of analysts have recently commented on EBS shares. Zacks Research raised Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. initiated coverage on shares of Emergent Biosolutions in a research note on Friday, August 21st. They set an “underweight” rating on the stock. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Emergent Biosolutions has an average rating of “Hold” and a consensus target price of $10.00.

Insider Activity

In other Emergent Biosolutions news, Director Donald Degolyer sold 17,800 shares of the stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total value of $126,202.00. Following the completion of the sale, the director directly owned 111,921 shares in the company, valued at $793,519.89. This represents a 13.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by company insiders.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.